Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Treatment for Locally Advanced Gastroesophageal Junction Tumors
NCT07859410Not yet recruiting
- Sponsor
- Anhui Medical University
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of sintilimab in gastroesophageal junction adenocarcinoma, sponsored by Anhui Medical University. Primary endpoint: Pathological Complete Response Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07859410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859410.